Published: 24 February 2026WHOHealth
Zimbabwe Launches Lenacapavir HIV-Prevention Injection — India Generics Link
Zimbabwe became one of the first countries in the world to launch lenacapavir, a groundbreaking twice-yearly injectable drug for HIV prevention, in February 2026. The drug, developed by Gilead Sciences, works as a capsid inhibitor — a novel mechanism that disrupts the HIV virus's protein shell, preventing it from replicating inside the human body.
Clinical trials showed approximately 100% efficacy in preventing HIV infection among high-risk populations, making it one of the most effective HIV prevention tools ever developed. Zimbabwe rolled out the injection across 24 sites nationwide, targeting women and girls who are disproportionately affected by HIV in sub-Saharan Africa.
A key dimension for India is the licensing arrangement: Gilead Sciences has signed voluntary licensing agreements with six generic manufacturers — Dr Reddy's Laboratories, Emcure, Eva Pharma, Ferozsons Laboratories, Hetero and Mylan (a Viatris subsidiary) — to support lenacapavir supply across 120 primarily low- and lower-middle-income, high-incidence resource-limited countries. This reflects India's central role in global health equity as the "pharmacy of the world."
The World Health Organization (WHO) has endorsed the drug's potential to transform HIV prevention globally. Unlike daily oral PrEP (pre-exposure prophylaxis), the twice-yearly injection significantly reduces the burden of adherence, making it more practical for populations in resource-limited settings.
For RAS aspirants, this story is relevant to topics on global health governance, India's pharmaceutical export role, public health equity, and international cooperation in combating communicable diseases.
0Mains angle
Q: Discuss Zimbabwe's February 2026 lenacapavir rollout and its significance for India's role as the 'pharmacy of the world' in global HIV prevention.
Answer (50 words):
In February 2026, Zimbabwe rolled out Gilead's twice-yearly lenacapavir HIV-prevention injection across twenty-four sites, targeting high-risk women. Trials showed near-total efficacy through capsid-inhibition. Gilead licensed six generic makers — Dr Reddy's, Emcure, Eva Pharma, Ferozsons, Hetero and Mylan (Viatris) — for 120 primarily low- and lower-middle-income, high-incidence countries, reinforcing India's generics leadership and WHO-endorsed global health equity.
6-axis classification
CoverageInternationalSubjectScience & TechnologyExamBasic Computer Instructor · CET Graduation · CET Senior Secondary · EO/RO · LDC · Mahila Supervisor · Patwar · PTI · RAS · REET · RPSC SI · School Lecturer · Senior Computer Instructor · Senior Teacher · UPSC · Vanpal · BothSourceWHO
Frequently asked questions
What is lenacapavir and how does it work?
Lenacapavir is a twice-yearly injectable HIV prevention drug (PrEP) developed by Gilead Sciences. It is a capsid inhibitor that disrupts the protein shell of HIV, preventing viral replication.
Which manufacturers are licensed to produce lenacapavir?
Gilead Sciences has signed voluntary licensing agreements with six generic manufacturers — Dr Reddy's Laboratories, Emcure, Eva Pharma, Ferozsons Laboratories, Hetero and Mylan (a Viatris subsidiary) — to support lenacapavir supply across 120 primarily low- and lower-middle-income, high-incidence resource-limited countries.
What efficacy did lenacapavir show in trials?
Clinical trials showed approximately 100% efficacy in preventing HIV infection among high-risk populations.
Why is Zimbabwe's launch significant?
Zimbabwe is among the first countries globally to launch lenacapavir, deploying it across 24 sites with a focus on women and girls disproportionately affected by HIV.
How is lenacapavir different from existing PrEP?
Unlike daily oral PrEP pills, lenacapavir is injected just twice a year, greatly reducing the adherence burden for patients in resource-limited settings.
